Kagan R - Search Results

1

Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, Ottery FD. Kagan R, et al. Adv Ther. 2024 Dec 30. doi: 10.1007/s12325-024-03073-8. Online ahead of print. Adv Ther. 2024. PMID: 39739195

2

Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R. Morga A, et al. Among authors: kagan r. Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27. Menopause. 2024. PMID: 38016166

3

Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause.

Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M; Breeze 3 Investigators. Pinkerton JV, et al. Among authors: kagan r. Menopause. 2014 Jun;21(6):567-73. doi: 10.1097/GME.0b013e3182a7c073. Menopause. 2014. PMID: 24149930 Clinical Trial.

4

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

Kagan R, Simon JA, Goldstein SR, Komm BS, Jenkins SN, Portman DJ. Kagan R, et al. Menopause. 2024 Jun 1;31(6):494-504. doi: 10.1097/GME.0000000000002355. Epub 2024 Apr 23. Menopause. 2024. PMID: 38652875 Clinical Trial.

5

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.

Mirkin S, Pinkerton JV, Kagan R, Thompson JR, Pan K, Pickar JH, Komm BS, Archer DF. Mirkin S, et al. Among authors: kagan r. J Womens Health (Larchmt). 2016 May;25(5):431-42. doi: 10.1089/jwh.2015.5351. Epub 2016 Apr 8. J Womens Health (Larchmt). 2016. PMID: 27058301 Clinical Trial.

6

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

Lobo RA, Archer DF, Kagan R, Kaunitz AM, Constantine GD, Pickar JH, Graham S, Bernick B, Mirkin S. Lobo RA, et al. Among authors: kagan r. Obstet Gynecol. 2018 Jul;132(1):161-170. doi: 10.1097/AOG.0000000000002645. Obstet Gynecol. 2018. PMID: 29889748 Clinical Trial.

7

The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.

Kagan R. Kagan R. J Womens Health (Larchmt). 2012 Sep;21(9):975-81. doi: 10.1089/jwh.2011.3448. Epub 2012 Jul 3. J Womens Health (Larchmt). 2012. PMID: 22759213 Review.

8

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, Mirkin S. Constantine GD, et al. Among authors: kagan r. Menopause. 2019 May;26(5):513-519. doi: 10.1097/GME.0000000000001261. Menopause. 2019. PMID: 30516713 Free PMC article. Clinical Trial.

9

Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.

Portman DJ, Goldstein SR, Kagan R. Portman DJ, et al. Among authors: kagan r. Climacteric. 2019 Feb;22(1):65-72. doi: 10.1080/13697137.2018.1535583. Epub 2018 Dec 17. Climacteric. 2019. PMID: 30554531 Free article. Review.

10

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.

Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. Kagan R, et al. Menopause. 2010 Mar;17(2):281-9. doi: 10.1097/GME.0b013e3181b7c65f. Menopause. 2010. PMID: 19779382 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters